DEF 14A: Innovate Corp. Seeks Stockholder Approval for Officer Exculpation, Share Increase, Reverse Stock Split, and Equity Plan Amendment

Innovate Corp. is asking stockholders to vote on several key proposals at its 2024 Annual Meeting, including amendments to the certificate of incorporation and equity award plan.

Summary

• Innovate Corp. is holding its 2024 Annual Meeting on June 13, 2024, virtually.
• Stockholders will vote on several proposals, including the election of four directors, an advisory vote on executive compensation, and amendments to the company's certificate of incorporation.
• Proposed amendments include officer exculpation, increasing authorized common stock, implementing a reverse stock split (ratio between 1-for-2 and 1-for-10), and increasing shares available under the 2014 Omnibus Equity Award Plan.
• The company is also seeking approval for vesting restricted stock units and stock options granted to the Interim CEO and for the conversion of Series C Preferred Stock into Common Stock in connection with a rights offering.
• The board recommends voting FOR all proposals.
• The company achieved several financial and strategic objectives during fiscal year 2023, including gross margin growth at DBM Global and momentum in the healthcare industry for Pansend Life Sciences.
• DBM Global's revolving line of credit maturity date was extended to August 15, 2025.
• MediBeacon issued $7.5 million of its preferred stock to Huadong Medicine Co., Ltd.
• The company closed the sale of the remaining 19% interest in HMN International Co. Ltd.
• The company consummated the purchase of all the Series A Preferred Stock issued by DBM Global Intermediate Holdco Inc. for $42.2 million.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. While there are positive developments in some business segments, the NYSE listing issue and the need for a reverse stock split introduce uncertainty. The sentiment is neutral to slightly positive.

Positives

• DBM Global's gross margin increased to 14.6% and Adjusted EBITDA margin to 7.2% for the year ending December 31, 2023.
• DBM Global's revolving line of credit maturity date was extended to August 15, 2025.
• Pansend Life Sciences portfolio companies R2 Technologies, Inc. and MediBeacon, Inc. are making solid progress.
• R2 launched Glacial fx in the third quarter 2023 in the United States and Canada, and sold out of all Glacial fx inventory in the fourth quarter 2023.
• R2 achieved record growth in North America for both system sales and number of patients treated.
• Broadcasting entered into agreements with PBS stations for new commercial opportunities with ATSC 3.0.
• The company closed the sale of the remaining 19% interest in HMN International Co. Ltd.
• The company consummated the purchase of all the Series A Preferred Stock issued by DBM Global Intermediate Holdco Inc.

Negatives

• The company received a notification from the NYSE stating that the closing price for its Common Stock had been below $1.00 for the previous 30 consecutive trading days.
• The company is subject to the procedures outlined in Sections 801 and 802 of the NYSE Listed Company Manual.
• The company has a cure period of six months, or until August 26, 2024, in which to regain compliance.
• The company's Common Stock could be delisted from the NYSE if it fails to regain compliance.
• The company's shares may then be quoted on the OTC Bulletin Board or other small trading markets, which are generally considered to have less volume and be less efficient markets.
• The company's Common Stock could trade thinly as a microcap or penny stock, decrease to nominal levels of trading and be unattractive to retail and institutional investors, impairing the liquidity of our Common Stock.

Risks

• Failure to approve the reverse stock split may have serious, adverse effects on the Company and its stockholders.
• The proposed Reverse Stock Split may decrease the liquidity of our Common Stock and result in higher transaction costs.
• The company may not satisfy the NYSE continued listing requirements following the Reverse Stock Split.
• A decline in the market price of our Common Stock after the Reverse Stock Split is approved and effected may result in a greater percentage decline than would occur in the absence of the Reverse Stock Split.
• The company may lose the confidence of its business partners, which would jeopardize its ability to continue its business as currently conducted.
• The price of the company's Common Stock will likely decrease as a result of the loss of market efficiencies associated with NYSE and the loss of federal preemption of state securities laws.
• Holders may be unable to sell or purchase the company's securities when they wish to do so.
• The company may become subject to stockholder litigation.
• The company may lose the interest of institutional investors in its Common Stock.
• The company may lose media and analyst coverage.
• The company's Common Stock could be considered a penny stock, which would likely limit the level of trading activity in the secondary market for its Common Stock.
• The company would likely lose any active trading market for its Common Stock, as it may only be traded on one of the over-the-counter markets, if at all.

Future Outlook

The company believes its Infrastructure, Life Sciences and Spectrum segments are well positioned to take advantage of current trends and that there is opportunity to build value organically and inorganically in these three segments.

Management Comments

• The Company is committed to active engagement and meaningful ongoing dialogue with our stockholders.
• We believe that a culture of transparency with our stockholders will enable us to deliver sustainable, long-term value by ensuring that our objectives and vision for the Company are aligned.

Industry Context

The document highlights Innovate Corp.'s diversified holdings across infrastructure, life sciences, and spectrum, reflecting a trend among holding companies to operate across multiple sectors to mitigate risk and capitalize on diverse growth opportunities.

Comparison to Industry Standards

• DBM Global's gross margin of 14.6% and Adjusted EBITDA margin of 7.2% can be compared to companies like AECOM and Fluor Corporation in the infrastructure sector.
• R2 Technologies' launch of Glacial fx and sales growth can be benchmarked against companies like Cynosure and Cutera in the aesthetic dermatology market.
• MediBeacon's partnership with Huadong Medicine Co., Ltd. is similar to other collaborations in the life sciences industry, such as those between Amgen and BeiGene.
• HC2 Broadcasting Holdings Inc.'s agreements with PBS stations for new commercial opportunities with ATSC 3.0 can be compared to companies like Sinclair Broadcast Group and Nexstar Media Group in the broadcasting industry.

Related Party Transactions

• During the year ended December 31, 2022, R2 Technologies, Inc. (R2) entered into various note purchase agreements with Lancer Capital LLC (Lancer Capital), an entity controlled by Avram A. Glazer, the Chairman of INNOVATE's Board of Directors, for an aggregate $10.8 million in notes at a 18% per annum interest rate as of December 31, 2022.
• In December 2023, the Company entered into a sublease agreement with Palm Beach Cultural Innovation Center, Inc. (PBCIC), a Florida not-for-profit corporation and related party to Avram A. Glazer, the Chairman of INNOVATE's Board of Directors, who is also on the board of directors of PBCIC.
• Lancer Capital held $2.0 million of principal amount of the Company's $51.8 million 7.5% 2026 Convertible Notes, as of both December 31, 2023 and 2022.

Stakeholder Impact

• Shareholders will be impacted by the proposed reverse stock split, which could affect the share price and liquidity.
• Employees may be impacted by changes to the equity award plan.
• The company's ability to attract and retain key personnel could be affected by the proposed changes to the equity award plan.
• The company's business partners may be impacted by the potential delisting from the NYSE.

Next Steps

• Stockholders to vote on proposals at the 2024 Annual Meeting on June 13, 2024.
• Board to determine whether and when to implement the reverse stock split and which ratio to use.
• Company to file a certificate of amendment with the Secretary of State of the State of Delaware if the reverse stock split is approved.
• Company to file a prospectus supplement to an existing registration statement on Form S-3 or a new registration statement on Form S-3 providing for the resale from time to time by Lancer Capital of the Registrable Common Stock.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, reverse stock split, officer exculpation, common stock, equity award plan, directors, executive compensation, innovate corp